Theriva Biologics Valuation

Is SFY0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SFY0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SFY0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SFY0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SFY0?

Key metric: As SFY0 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SFY0. This is calculated by dividing SFY0's market cap by their current book value.
What is SFY0's PB Ratio?
PB Ratio	0.1x
Book	US$24.64m
Market Cap	US$2.86m

SFY0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SFY0's PB Ratio compare to its peers?

The above table shows the PB ratio for SFY0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	16.8x
T5O bioXXmed	14.4x	n/a	€1.6m
CNW co.don	1x	n/a	€6.5m
MDG1 Medigene	1.2x	-4.1%	€23.2m
VSC 4SC	50.8x	n/a	€58.0m
SFY0 Theriva Biologics	0.1x	-8.9%	€2.9m

Price-To-Book vs Peers: SFY0 is good value based on its Price-To-Book Ratio (0.1x) compared to the peer average (22.9x).

Price to Book Ratio vs Industry

How does SFY0's PB Ratio compare vs other companies in the DE Biotechs Industry?

4 Companies	Price / Book	Estimated Growth	Market Cap
Industry Avg.	2.3x	42.7%
SFY0 Theriva Biologics	0.1x	-8.9%	US$2.86m
V9Z Aceragen	0.1x	n/a	US$3.12m
V9Z Aceragen	0.1x	n/a	US$2.18m

4 Companies		Estimated Growth	Market Cap
Industry Avg.	2.3x	42.7%
SFY0 Theriva Biologics	0.1x	-8.9%	US$2.86m

No more companies

Price-To-Book vs Industry: SFY0 is good value based on its Price-To-Book Ratio (0.1x) compared to the European Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is SFY0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SFY0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SFY0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.1b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$710.80

-7.8%

-3.7%

Aspen Pharmacare Holdings

R76.1b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

-0.6%

7.1%

Pharming Group

€475.9m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

-2.0%

-33.5%